The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
Louise A. Knight,Federica Di Nicolantonio,Pauline A. Whitehouse,Stuart Mercer,Sanjay Sharma,Sharon Glaysher,Penny Johnson,Ian A. Cree +7 more
TLDR
The in vitro model suggests that gefitinib may have differential effects in response to concomitant cytotoxic chemotherapy with the agents tested during this study, and represents the first use of a TKI in the assay.Abstract:
Background
Activation of the epidermal growth factor receptor (EGFR) triggers downstream signaling pathways that regulate many cellular processes involved in tumour survival and growth. Gefitinib ('Iressa') is an orally active tyrosine kinase inhibitor (TKI) targeted to the ATP-binding domain of EGFR (HER1; erbB1).read more
Citations
More filters
Journal ArticleDOI
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
TL;DR: The current status of anti-EGFR agents and the recurrent problem of resistance to these agents that strongly indicates that a multiple target approach will provide a more favorable future for these types of targeted therapies in GBM.
Journal ArticleDOI
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
TL;DR: This review explains EGFR and EGFRvIII signaling in GBM; describes targeted therapy approaches to date including tyrosine kinase inhibitor, antibody- based therapies, vaccines and pre-clinical RNA-based therapies, and discusses the difficulties encountered with these approaches including pathway redundancy and intratumoral heterogeneity.
Journal ArticleDOI
Targeted therapy for uveal melanoma.
TL;DR: The prospects for improving the systemic therapy of uveal melanoma using molecularly targeted agents that are currently in clinical use as well as agents being tested in clinical trials are focused on.
Journal ArticleDOI
Pancreatic cancer : from molecular pathogenesis to targeted therapy
TL;DR: This review presents the main pathophysiological alterations met in pancreatic cancer and the results of the florid preclinical and clinical research with regards to the targeted therapy associated to these abnormalities.
Journal ArticleDOI
Regulators of homologous recombination repair as novel targets for cancer treatment.
TL;DR: This review discusses how the mechanistic wiring of HR is controlled by cell-intrinsic or extracellular pathways, and performs a meta-analysis on available genome-wide RNA interference studies to identify additional pathways that control HR repair.
References
More filters
Journal ArticleDOI
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more
TL;DR: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Journal ArticleDOI
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Thomas J. Lynch,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +15 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +14 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy as mentioned in this paper.
Journal ArticleDOI
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone,Roy S. Herbst,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Vincent A. Miller,Ronald B. Natale,Joan H. Schiller,Joachim von Pawel,Anna Pluzanska,Ulrich Gatzemeier,John Grous,Judith S. Ochs,Steven D. Averbuch,Michael K. Wolf,Pamela Rennie,Abderrahim Fandi,David H. Johnson +17 more
TL;DR: Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitABine and cascplatin alone, and the reasons for this remain obscure and require further preclinical testing.
Journal ArticleDOI
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Roy S. Herbst,Giuseppe Giaccone,Joan H. Schiller,Ronald B. Natale,Vincent A. Miller,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Ira Oliff,James A. Reeves,Michael K. Wolf,Annetta D. Krebs,Steven D. Averbuch,Judith S. Ochs,John Grous,Abderrahim Fandi,David H. Johnson +16 more
TL;DR: This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials and showed no added benefit in survival, time to progression, response rate (TTP), or RR compared with standard chemotherapy alone.
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone,Roy S. Herbst,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Vincent A. Miller,Ronald B. Natale,Joan H. Schiller,Joachim von Pawel,Anna Pluzanska,Ulrich Gatzemeier,John Grous,Judith S. Ochs,Steven D. Averbuch,Michael K. Wolf,Pamela Rennie,Abderrahim Fandi,David H. Johnson +17 more
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more